Furthermore, the European Commission Initiative on Breast Cancer recommended the use of Oncotype Dx® RS in ER + /HER2-, N0 BC patients to assess the benefit of adjuvant CHT, whereas the Mammaprint® 70-genes risk score should be used only in clinical high-risk patients as defined in MINDACT trial17. The gene discussed is ERBB2; the disease is breast cancer.